• A Study Testing mRNA-1273 Vaccine Safety and Effectiveness Against Severe COVID-19 in Adults Aged 50-64 Years Without Risk Factors

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Denmark
  • Study of BNT111 and cemiplimab in patients with advanced melanoma who have not responded to other therapies

    Not recruiting

    2 1 1 1
    Germany Italy Poland Spain
  • A study looking at the safety of switching from emicizumab to denecimig in adults and adolescents with haemophilia A with or without inhibitors

    Not recruiting

    3 1 1
    Austria Belgium France Germany Italy Spain
  • A study testing cagrilintide and semaglutide compared to placebo in people with type 2 diabetes not well controlled by diet and exercise

    Not recruiting

    3 1
    Investigated Diseases:
    Investigated Drugs:
    Hungary Italy Poland
  • Study of Tozorakimab for Patients with Chronic Obstructive Pulmonary Disease Who Have Symptoms and a History of Flare-ups

    Not recruiting

    3 1 1
    Investigated Diseases:
    Belgium Bulgaria Czechia Denmark Finland Hungary +5
  • A Study of Cizutamig for Patients with Severe Autoimmune Inflammatory Diseases That Did Not Respond to Previous Treatments

    Not recruiting

    1 1 1
    Germany
  • A study testing vipoglanstat for women with moderate to severe endometriosis-related pain

    Not recruiting

    2 1
    Investigated Drugs:
    Bulgaria Czechia Hungary Italy Poland Romania
  • A Study of ALN-6400 Safety and Effectiveness in Adults with Hereditary Hemorrhagic Telangiectasia

    Not recruiting

    1 1
    France Germany Spain
  • A study on ovulation inhibition with norelgestromin patch after missed applications in women who need birth control

    Not recruiting

    2 1 1
    Investigated Drugs:
    Germany
  • A Study of Lifileucel with Cyclophosphamide, Fludarabine, and Aldesleukin for Adults with Previously Treated Advanced Melanoma

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    France Germany Italy Spain

powered by